Research programme: tissue protective cytokines - Warren Pharmaceuticals
Alternative Names: TCP-1; TCP-2; WP 101Latest Information Update: 04 Nov 2017
At a glance
- Originator Warren Pharmaceuticals
- Class Cytokines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders; Eye disorders; Spinal cord injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Eye-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA